Epicardial adipose tissue (EAT) is an atypical fat depot surrounding the heart with a putative role in the development of atherosclerosis.
Introduction
Epicardial adipose tissue (EAT) thickness and volume strongly reflect obesity, intra-abdominal visceral fat, and insulin resistance.
1,2 Indeed, EAT thickness is an independent risk factor for coronary artery disease (CAD), atrial fibrillation, and other cardiac diseases. 3 -5 EAT surrounds heart muscle and coronary arteries, and shares with these organs the same microcirculation. 6 EAT vascularization is supplied by branches of the coronary arteries, and no muscle fascia divides EAT from the myocardium. 7 Under physiological conditions, different metabolic, cardioprotective, and thermogenic ('brown-like ') functions have been attributed to EAT, 1, 8 that can vary depending on EAT anatomical location. 9 A substantial inflammatory infiltrate has been described in EAT, since EAT produces several bioactive molecules, including pro-inflammatory cytokines 9 -12 that could be paracrinally or vasocrinally secreted to the myocardium and to the coronary artery wall. EAT could thus be able to modulate heart and coronary artery physiology, 13 and mounting evidences point to EAT as a candidate player in pathophysiology of CAD and cardiac disease. 1, 13 miRNAs are small, non-coding RNAs acting as fine posttranscriptional tuners of gene expression, either interfering with protein translation or reducing transcript levels.
14 miRNAs act on multiple targets and complex pathways, thus representing candidate regulators of metabolic homeostasis, adipocyte differentiation, AT function, and inflammation. 15 miRNAs have also been described as differentially modulated in adipose tissue during metabolic disease, thus being considered candidate biomarkers for metabolic disease and CAD, and putative targets for therapy. 16, 17 In the present study, we depicted a comparative miRNA and wholegenome expression chart from EAT and subcutaneous adipose tissue (SAT) in 'metabolically healthy' patients without CAD and in metabolic patients with CAD. This strategy allowed us to identify a set of genes/ miRNA characterizing EAT in health and disease as well as novel biological processes characterizing EAT in CAD. Also, we characterized CCL13/MCP4 as a putative biomarker of CAD.
Methods summary
Forty-four Caucasian male patients were recruited at the University of Bologna; 15 underwent cardiac valve surgery (CTRL group; no history/ evidences of CAD/carotid atherosclerosis; ,1 criterion for Metabolic Syndrome, MS), and 29 underwent coronary artery bypass graft surgery (CAD group). Gene/miR microarray expression analyses were conducted on RNA extracted from SAT and perivascular EAT using the 'Illumina HumanHT-12-V3' and 'Human-V2-MicroRNA' Expression Kits (Illumina iScan). Data were processed using Illumina Genome Studio, SAS software, and R package. Differentially expressed genes were studied using Ingenuity Pathway Analysis (Ingenuity System Inc., USA). Microarray data are available on GEO (Ref: GSE64566; http://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc=GSE64566). Quantitative PCR confirmations were performed to validate genes (High Capacity DNA Archive Kit and Power Sybr Green, Applied Biosystem) and miRNAs (TaqMan miRNA Assays, Applied Biosystems). Formalin-fixed adipose tissue specimens were used for H&E and IF. Circulating RANTES and MCP-4 in the serum were determined by commercially available ELISA kits (RayBiotech, Inc.). Microarray analysis was performed in 23 subjects; RT-qPCR confirmations in 41 subjects; IF in 14 subjects; serum cytokine analysis in 43 subjects plus an external validation cohort (19 subjects) of patients with risk factors of CAD (Study design in Supplementary material online, Figure S1 ). Human heart pre-adipocytes (HPAd) and human kidney (HEK-293) cells were obtained from Public Health England (PHE) and American Type Tissue Collection (ATTC), respectively. HPAd cells were differentiated following manufacturer's instructions. miRIDIAN hsa-miR-103 mimic and hairpin inhibitor, or negative controls (Thermo Scientific) were transfected using Lipofectamine LTX following manufacturer's instructions (Invitrogen) in differentiated adipocytes. 3 ′ UTR Luciferase Reporter Assay was performed using HEK-293 cells, hsa-miR-103 mimic and hairpin inhibitor, or negative controls, together with 3 ′ UTR or 3 ′ UTR mutant (deletion of miR-103 target sequence) provided by Genecopoeia. Luciferase activity (Firefly/Renilla luciferase ratio) was measured using the Dual-Glo Luciferase Assay (Promega). Detailed experimental procedures are provided in the Supplementary material.
Results

Study population
We enrolled 29 CAD patients (93% with MS) and 15 'controls' (CTRL), namely subjects undergoing cardiac valve replacement (n ¼ 15, with ≤1 Adult Treatment Panel III -ATPIII criteria for MS) with negative clinical and instrumental evidences of atherosclerosis and CAD. Compared with 'controls', CAD patients were characterized by significantly increased abdominal circumference (AC), BMI, systolic blood pressure, heart rate, glycaemia, and systemic inflammation, while HDL-c was decreased. Characteristics of the study population are provided in Supplementary material online, Table S1A and B.
A specific gene expression matrix characterizes EAT from SAT
To measure the gene expression patterns that characterize EAT from SAT, we used the whole-genome microarrays. Overall, the signal intensity of 1131 genes resulted statistically different at the Wilcoxon signed-rank test in EAT (vs. SAT), thus underscoring the profound diversity of EAT and SAT. To depict atherosclerosis-independent and -dependent peculiarities of EAT vs. SAT, we selected 421 annotated genes ( Figure 1A ; 173 down-regulated, see Supplementary material online, Table S2B ; 248 up-regulated, see Supplementary material online, Table S2D ) that were significantly different (EAT vs. SAT) in the overall population (P , 0.01; FDR , 0.01) and at least in one of the two subgroups (CTRL or CAD; Cut-off: P , 0.05, fold change . 1.5). To provide a framework for interpretation of our results, we then functionally clustered significant biological pathways using the Core Function of Ingenuity System Pathway Analysis (IPA; see Supplementary material online, Table S2A and C). We considered 'biologically relevant' only those 'statistically significant' items included in 'significantly modulated' pathways. EAT profiling revealed a clear 'inflammatory scenario' both in CTRL and in CAD, as confirmed by the up-regulation of pro-inflammatory pathways, macrophage surface antigens (CD14 and CD163), and cytokines. In addition to the up-regulation of inflammatory mediators previously described in EAT of CAD subjects (i.e. IL6; chemoattractant protein-1, MCP-1; CCL5/RANTES; intercellular adhesion molecule 3, ICAM3/CD50; chemokine C-C motif ligand 8, CCL8/MCP-2; 'neutrophil chemotactic factor' IL8; CCL21/6Ckine; chemokine C-X-C motif ligand 2, CXCL2; IL-7 receptor, IL-7R), 9 -12,18,19 we also profiled an increase of other key players in inflammation (e.g. CCL13/MCP-4; tolllike receptor 5, TLR5), and VEGFC. Pro-inflammatory signals were more prominent in CAD patients, while reduced 'extracellular matrix deposition and fibrosis', inhibition of the oxysterol sensor Liver X Receptor (LXR), and Phosphatase and Tensin Homologue (PTEN) activation were more prominent in the EAT of the CTRL group. Using the Random Forest (RF) algorithm, we then studied the ability of our set of genes to characterize EAT from SAT. RF is able to 'score', in order of 'relative importance' (RI, see Supplementary material online, Table S2B and D), the capability of each variable to distinguish two specific conditions. According to RF, 14 differentially modulated genes (EAT vs. SAT; Figure 1B ) characterize the 'identity card' of EAT from SAT independently from patients' disease. This list features 4 upregulated and 10 suppressed genes. Indeed, the accuracy of these genes in distinguishing EAT from SAT has been estimated by the algorithm as high as 100% (C-Index ¼ 1; Figure 1C) .
Overall, we provided a comprehensive CAD-independent gene expression signature of EAT vs. SAT, and we showed that increased inflammatory signals are not necessarily associated to the concomitant presence of CAD. These features sustain the novel concept that inflammation is required for a proper adipose tissue function, 20 and that the presence of inflammatory infiltrates as well as a generic over-activation of inflammatory signals not necessarily predict the presence of disease.
Epicardial adipose tissue in atherosclerosis 3.3 A specific miRNA expression matrix characterizes EAT from SAT The second step was to define the miRNome characterizing EAT vs. SAT in the overall population. In the entire study group samples, 6 miRNAs were significantly up-regulated and 19 down-regulated in EAT vs. SAT (Wilcoxon signed-rank test, P ≤ 0.01; FDR ≤ 0.1; fold change . 1.5 in CTRL or CAD subgroup; Figure 2A and see Supplementary material online, Table S3 ). In the up-regulated miRNAs, of particular interest is miR-146b-5p known to promote adipogenesis. 15 Five miRNAs were significantly down-regulated in the overall population and in both subgroups of patients (CTRL and CAD; Figure 2B ), thus being characteristic of EAT vs. SAT, independently from the presence of CAD. These EAT-specific miRNAs are miR-196b-5p, miR-196a-5p (a promoter of brown adipogenesis 21 ), miR-18a-3p (a member of the miR-17/92 cluster that promotes adipocyte differentiation 22 ), and miR-10a-3p (an anti-inflammatory agent 23 ). Some of these miRNAs could coordinately sustain the pro-inflammatory profile emerged from the whole-genome analysis; for example, we profiled a suppression of the anti-inflammatory miR-10a-3p and miR-23a-5p that have been shown to target monocyte chemotactic protein 1 (MCP-1), IL6, and IL8 23, 24 (up-regulated in EAT vs. SAT).
According to RF, the differential modulation of miR-196a-5p and miR-19b-5p is highly specific for EAT (see Relative Importance, RI, in Supplementary material online, Table S3 and patterns of expression in Figure 2B ), and the levels of expression of these two miRNAs characterize EAT with an accuracy of 74% (C-Index ¼ 0.74; Figure 2C ).
Overall, we were able to depict a novel miRNA signature of EAT vs. SAT characterized by an up-regulation of miRNAs that are able to promote adipogenesis (miR-146b-5p) and a suppression of antiinflammatory miRNAs (miR-23a-5p and miR-10a-3p).
A specific microRNA matrix characterizes EAT in CAD
We then characterized CAD-specific miRNA expression changes in EAT. Compared with CTRL group, the expression patterns of 15 miRNAs appeared to be significantly up-regulated (Mann-Whitney U test, P , 0.05; FDR ≤ 0.3; fold change . 1.2), while 14 miRNAs downregulated ( Figure 3A and see Supplementary material online, Table  S4A ,B; Changes in SAT for comparison are reported in Supplementary material online, Table S4 C and D). In EAT of CAD patients, we found increased miR-135b-3p (a direct target of inflammatory pathways 25 ),
while Let-7a-3p and miR-127-3p (negative modulators of inflammatory pathways 16, 26 ) were down-regulated. In EAT of CAD patients, we also found suppressed miR-455-3p (a driver of during brown adipocyte differentiation 27 ), miR-193b-3p (promoting adiponectin secretion in human adipocytes), 28 miR-30a-5p and miR-103-3p (but not of miR-103-3p paralogous miR-107, see qPCR confirmation in Supplementary material online, Figure S2C ). miR-30a-5p and miR-103-3p are considered key players in white adipose tissue differentiation and function. Indeed, these miRNAs are induced during adipogenesis and can accelerate this process when ectopically overexpressed. 29, 30 miR-30a-5p is known to be down-regulated in obesity, 29 ,31 while there Table S2 .
is no agreement with regard to miR-103-3p expression changes (see below). We confirmed the differential changes of miR-30a-5p, miR-103-3p, miR-135b-3p, and miR-651-5p by RT -qPCR ( Figure 3B ) in the expanded population and analysed our data with the RF algorithm: although not massively differentially modulated, changes in these miRNAs predict the 'CAD status' with a high accuracy (C-Index: 0.75, Figure 3C ). We thus provided the evidence that patients with CAD present differentially modulated EAT-specific miRNA expression patterns. Since candidate miRNAs are considered players in inflammation (i.e. miR-135b-3p, miR-193b-3p, and Let-7a-3p) and adipocyte function (i.e. miR-455-3p, miR-30a-5p, and miR-103-3p), our data elect these miRNAs as putative actors in the pathophysiological events characterizing EAT inflammation in MS, as well as their potential involvement in CAD.
Repression of metabolic and RXR-heterodimer pathways is distinctive of CAD in EAT
We then characterized a matrix of EAT gene pathways suppressed in CAD. The signal intensity of 89 genes were significantly downregulated in CAD patients (Mann -Whitney U test, P , 0.05; FDR ≤ 0.2; fold change . 1.2 vs. CTRL; Figure 4A and see Supplementary material online, Table S5B . Changes in SAT for comparison are reported in Supplementary material online, Figure S3 and detailed in Supplementary material online, Table S5C and D). Both IPA pathway analysis (see Supplementary material online, Table S5A ) and IPA 'upstream regulator' prediction tool [that predicts the status of activation of a specific modulator (e.g. a transcription factor) on the basis of the differential modulation of its known targets; Figure 5A ] featured a down-regulation of the predicted as inhibited on the basis of its downstream targets. We confirmed the suppression of the most represented genes in the pathway analysis (RXRa, LPL, and PTEN) in EAT of CAD patients (transcript by RT-qPCR and of proteins by IF; Figure 5B and C, respectively). These molecular patterns point to an intriguing down-regulation of genes involved in lipid metabolism, mitochondrial function, and lipid-and retinoid-sensing NR transcriptional activation in EAT of patients with CAD. These findings are of particular interest since: (i) NRs transcription factors act as key players in the modulation of metabolic homeostasis, inflammation, and circadian rhythms, and could influence cardiometabolic disease and pro-inflammatory signals in EAT; 35, 36 (ii) EAT has been described as an active metabolic tissue exhibiting 'beige' features 8 ; (iii) the presence of CAD has been associated to a 'brown-to-white' adipocyte transdifferentiation in EAT. 37 
Increased immune responses are distinctive of EAT in CAD
We also profiled 57 significantly (Mann -Whitney U test, P , 0.05; FDR ≤ 0.2; fold change . 1.2) up-regulated genes in EAT of CAD patients. The overexpressed interactome provided the evidence of an activation of both innate and adaptive immune responses in CAD, with an up-regulation of the MHC class II molecules (high-fat diet-induced MHC class II overexpression promotes macrophage accumulation in adipose tissue, and pro-inflammatory M1 polarization, 38, 39 while the deletion of MHC II leads to reduced accumulation of macrophages in the AT, improves insulin sensitivity, and protects form diet-induced obesity complications 40 ), an enhanced cross-talk among immunemodulatory cells, and a strong up-regulation of inflammatory cell growth, recruitment, and activity (details in Figure 4B and in Supplementary material online, Table S6A ,B; for comparison, SAT data in Supplementary material online, Figure S3 and Table S6C,D) . EAT is thus a source of mediators that could accumulate and retrieve monocytes in EAT and in the intima to differentiate into macrophages, a critical step in the development of the atherosclerotic plaque. 41 These genomic features support previous reports showing more pro-inflammatory EAT infiltrates in the CAD vs. CTRLs. 12, 42, 43 These results are of a particular value since atherosclerotic lesions develop mainly in the coronary arteries surrounded by fat, and EAT quantity and macrophage infiltration have been related to atherosclerotic plaque size and composition. 44 We thus provided the evidence of a complex over-activation of the inflammatory cascades in EAT of CAD patients at transcriptional level, pointing to the antigen presenting pathways (MHC Class II), the enhanced communication among inflammatory cells, and chemokine signalling (CCL5, CCL13, and CCL5R) as prominent features. This CAD-specific EAT profile could induce or, at least, sustain the systemic inflammatory response, and potentially promote coronary atherosclerosis.
Enhanced production and release of chemokines CCL5 and CCL13 in EAT of CAD patients
Given the prominent inflammatory profile characterizing EAT vs. SAT, we specifically focused on the inflammatory cytokines Chemokine C-C motif ligand 5 (CCL5/RANTES) and 13 (CCL13/MCP-4) that were the only chemokines increased in EAT of CAD patients (vs. controls). IPA also predicted CCR5 (CCL5 and CCL13 receptor) signalling as activated in EAT of CAD patients (vs. controls). The overexpression of these chemokines was confirmed by RT -qPCR in the expanded population ( Figure 6A and B) , and by IF (Figure 6C and D) . A pro-atherogenic role has been highlighted for both these chemokines. CCL5 has been previously described overexpressed in EAT of overweight and CAD patients, 18, 45 and its protein content is correlated positively to macrophage infiltration and inversely to calcification in the atherosclerotic plaque. 46 Although pathophysiologically very interesting for atherosclerosis plaque formation (CCL5 binds proteoglycans in the vascular walls, and its enrichment is associated with increased leucocyte extravasation 47, 48 ), serum CCL5 is not eligible as a coronary risk biomarker 46 since that CCL5 serum levels of CAD patients do not differ from those of controls ( Figure 6E) . The CCL13/MCP-4 chemokine is a central modulator of proinflammatory responses acting as a pan-agonist of different chemokine receptors (i.e. CCR2, CCR3, and CCR5). 49 The deletion of CCR2 or CCR5 is associated with reduced atherosclerosis in rodents, 50 -52 while CCR3 is overexpressed in human atherosclerosis and localized primarily to macrophage-rich regions of the atheroma. 53 CCL13 is also produced by other AT depots, including visceral 49 and paracardial AT, 13 and it has been suggested to positively feedback the release of other pro-atherogenic chemokines and promote atherosclerosis. 54 To test the potential of CCL13 as candidate biomarker of atherosclerosis, we then checked the levels of CCL13 protein in the systemic circulation, and we measured a significant increase in circulating CCL13 in CAD patients ( Figure 6F ). CCL13 has been described as increased also in overweight patients. 49 Since the BMI of our control group was close to normality, we could not exclude BMI as a bias for the analysis.
To overcome this potential limitation, we recruited a further validation cohort of 19 overweight-obese patients referred to coronarography for one or more additional cardiovascular risk factors and chest pain, clustered on the basis of the presence/absence of CAD (characterization of this validation cohort in Supplementary Methods and Supplementary material online, Table S1C ). Levels of CCL13 (but not of CCL5) in the serum of patients with CAD ('BMI . 25, CAD' group) were statistically increased compared with those without CAD for CCL13 ( Figure 6G and H ) . Multiple regression analysis of the two study populations confirmed CCL13 as dependent from the presence of CAD and independent from BMI ( Figure 6I ). We thus candidate serum CCL13 as CAD biomarker, with a sensitivity of 73% and a specificity of 67% in discriminating CAD from CTRL subjects ( Figure 6J ; Cut-off of 337.7 pg/mL; area under the ROC curve 0.75). Overall, although the usefulness of CCL13 testing in predicting coronary atherosclerosis and cardiovascular events need to be validated on larger population cohorts, our results point to EAT as one of the contributors of CCL13/ MCP-4 circulating levels, and to CCL13/MCP-4 as a candidate player in the pathophysiology of EAT inflammation in patients with coronary atherosclerosis, and as a putative biomarker of CAD.
miR-103-3p post-transcriptionally regulates CCL13 secretion in epicardial adipocytes
In search for miRNA likely to modulate inversely regulated mRNAs, we studied candidate mechanisms of CCL5 and CCL13 regulation. IPA 'miRNA target prediction tool' highlighted miR-103-3p (suppressed in EAT of CAD patients) as one of the candidate modulators of CCL13; this association was also predicted by other in silico analyses (Target Scan, miRbase, and microrna.org). miR-103-3p has been described as a key factor in adipocyte function. It is up-regulated during adipocyte differentiation and upon PPARg activation, and suppressed 59 In our dataset of overweight CAD patients, no significant changes in miR-103-3p expression were observed in SAT (vs. CTRL; see Supplementary material online, Figure  S2A ), but we found miR-103-3p (and its host gene PANK3, see Supplementary material online, Figure S2B ) suppressed exclusively in EAT. miR-103-3p gain of function during adipocyte differentiation has been shown to modulate insulin sensitivity 56 and adipocyte differentiation 29, 56 towards the modulation of key metabolic genes such as LPL (suppressed in our database), PPARg2 (predicted to be inhibited by IPA 'upstream regulator' analysis), and adiponectin. 29 To provide translational relevance to our observations, we thus checked the expression levels of miR-103-3p, miR-107, their hosting genes (PANK 1, 2, and 3), and CCL13 ( Figure 7A and B) during a 14-day differentiation protocol of human epicardial pre-adipocytes into adipocytes (differentiation assessed by Oil Red O staining and markers of adipocyte differentiation and metabolic activity, Figure 7C and D). As previously described in mouse models, 29 miR-103-3p (with its host gene PANK3) and miR-107 (with its host gene PANK2) were induced during adipogenesis, while CCL13 was conversely suppressed. We then ectopically modulated miR-103-3p transfecting both miR-103-3p mimics and inhibitors (see Supplementary material online, Figure S4A and B; the inhibitor targeted also miR-107 as previously described 56 ) in the differentiated adipocytes, and we showed that miR-103-3p was able to target CCL13 mRNA (other candidate target genes in Supplementary material online, Figure S4B ), thus affecting CCL13 intracellular protein and secretion ( Figure 7E and F ). The reporter assay (CCL13 miRNA 3 ′ UTR target sequence) confirmed CCL13 as a target of miR-103 ( Figure 7G ). The deletion of miR-103-3p target sequence ( Figure 7H ) on the 3 ′ UTR reporter assay abolished this effect. As a result of CCL13 modulation, miR-103-3p showed anti-inflammatory Figure 6 In CAD, EAT overexpresses CCL5 and CCL13; CCL13 may act as a candidate biomarker of CVD. RT -qPCR confirmation (13 CTRL vs. 28 CAD patients): relative mRNA expression levels of CCL5 (A) and CCL13 (B). GAPDH was used as reference gene, and values were normalized to data obtained from CTRL patients. Means are represented as bars; variability among patients is represented with a scatter plot ( †: patient). Statistical significance (P ≤ 0.05) was assessed by Mann-Whitney rank sum test. (C and D) IF (6 CTRL vs. 8 CAD patients) confirms CCL5 and CCL13 protein as increased in CAD patients (% of marked area quantified using the ImageJ software). Serum levels (quantified by ELISA kit) of CCL5 did not differ between CAD and control patients (E and F ), while CCL13 is significantly increased in the CAD group both in patients undergoing cardiac surgery (14 CTRL vs. 28 CAD patients) and in the external validation cohort of patients with BMI . 25 (G and H; 10 CAD vs. 9 CAD patients). Statistical significance (P ≤ 0.05) was assessed by the multivariate analysis keeping in consideration BMI value as a confounding factor. Modelling of CCL13 serum levels of the overall patients population (I; main study plus validation cohort) by multivariate analysis (25 , BMI . 25; CAD: Yes/No) and ROC curve (J ) showing that CCL13 is a putative peripheral biomarker of CAD (area under the ROC curve: 0.75; cut-off of 337.7 pg/mL; sensitivity of 73%; specificity of 67%).
effects (IL-6 and IL-1b); however, miR-103-3p ectopic regulation was also associated with a positive metabolic modulation, as shown by the promotion of different metabolic markers (LPL, PPARg2, adiponectin, 29 and RXRa).
These data point to a novel role of miR-103-3p in negatively regulating inflammatory pathways and promoting adipocyte metabolism. The down-regulation of this miRNA in metabolic disease and CAD could induce a pro-inflammatory shift in EAT of patients with obesity and CAD.
Discussion and conclusions
The increased prevalence of obesity is a public health burden. Obesity, adiposopathy, and insulin resistance induce EAT enlargement, inflammation, and dysfunction, 1 and trigger CAD. Understanding if changes in EAT physiology are cause of atherosclerosis or just an epiphenomenon of obesity is thus mandatory. Here we provide novel information to depict the molecular identity card (genome and miRNome) of EAT (vs. SAT) in health and disease. We then present evidence that compared with SAT, EAT is characterized by enhanced inflammation and a suppression of anti-inflammatory miRNAs, supporting the concept that active inflammatory infiltrates are required for a proper EAT function. 20 Given the close anatomic relationship between perivascular EAT and coronary arteries, 7, 9 and the positive correlation between EAT and the presence of coronary atherosclerosis, our results point to EAT as a putative actor in MS/CAD. We describe that EAT in CAD displays Figure 7 miR-103 modulates CCL13 in human epicardial primary adipocytes. CCL13 transcript (A; RT -qPCR) decreased while miR-103a-3p (with its host gene PANK3) and miR-107 (with its host gene PANK1) expression increased (B; RT -qPCR) in a time-dependent manner, during a 14-day differentiation protocol of human epicardial pre-adipocytes; Markers of differentiation (RT -qPCR, C) and Oil Red O Staining (D) confirmed the differentiation of preadipocytes into adipocytes. CCL13 mRNA and protein (intracellular and secreted) appeared to be differentially modulated by the transfection of miR-103 mimic (E) or inhibitor (F ). In Hek293 cells (G), miR-103 mimic (black) and inhibitor (grey) were transfected together with a CCL13 3 ′ UTR reporter construct, wild-type or mutated (red bar) in the miR-103 binding sequence (H; 'AUGCUGC' deletion in red); alterations of luciferase activity confirmed the ability of miR-103 to modulate CCL13; upon binding mutation, the modulation is lost. miR-103a-3p showed also an anti-inflammatory role (ILs) and a promotion of metabolic genes (I, miR-103 mimic; J, miR-103 inhibitor). Proteins, firefly luciferase activity, and mRNA levels were measured 48 h after transfection. To rule out unspecific effects, control cells were transfected with negative control miRNAs. U6snRNA and GAPDH were used as reference (housekeeping) for RT -qPCR, renilla luciferase activity as reference for reporter assay. Data are presented as means + SD. Statistical significance was assessed by the Mann-Whitney rank sum test (n: 3; *P ≤ 0.05) or Kruskal -Wallis tests (n: 3; P ≤ 0.05; 'a', equal to reference group; 'b', different from 'a'; 'c', different from 'a' and 'b'), when appropriated.
Epicardial adipose tissue in atherosclerosis affected metabolic pathways with suppression of lipid-and retinoidsensing NRs transcriptional activities, increased inflammatory infiltrates, activation of innate and adaptive immune responses with the antigen presenting pathways (MHC Class II), the enhanced communication among inflammatory cells, and chemokine signalling (CCL5, CCL13, and CCL5R) as prominent features. These genomic alterations are sustained and integrated by changes in the miRNome characterizing EAT in CAD. Our integrative analysis highlighted miR-103-3p as suppressed in EAT of CAD patients; we also showed that miR-103-3p modulation is one of the possible mechanisms (but reasonably not the exclusive) modulating CCL13/MCP-4 in EAT. Interestingly, CCL13 circulating levels are increased in CAD patients, thus highlighting this chemokine as candidate biomarker of CAD. Further experimental confirmation that the lipid-sensing NRs/miR-103-3p/CCL13 axis in EAT may be causative of CAD requires relevant animal models. Unfortunately, species differences are currently limiting this work. In mice, CCL13 is not conserved, and the lipid metabolism and EAT characteristics are very different from human. Inducing CAD in the murine model is likewise very difficult. Since changes in behaviour and NRs pharmacological modulation (e.g. TZDs) can modulate EAT physiology, 35, 60 future insights are needed to develop novel strategies aimed to prevent or delay EAT enlargement, dysfunction and inflammation in obesity, and to check its consequences in CAD progression. In this respect, miR-103-3p/CCL13 might represent a novel pair of key actors of EAT dysfunction with a bona fide prognostic value in CAD.
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